Alpha Cognition Inc. Common Stock (ACOG) News
Follow Alpha Cognition Inc. Common Stock (ACOG) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Alpha Cognition Sets Date to Report Third-Quarter 2026 Results
Alpha Cognition plans to report its third-quarter 2026 financial results and provide a business update.
EQUITY | Nov 02, 2026, 09:09 PM UTC
L
ACOG - Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACOG - Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EQUITY | Sep 09, 2026, 10:05 PM UTC
L
Alpha Cognition announces inducement grants under Nasdaq Rule 5635(c)(4)
EQUITY | Sep 09, 2026, 10:00 PM UTC
L
ACOG - Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACOG - Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EQUITY | Sep 01, 2026, 09:03 PM UTC
L
Alpha Cognition reports inducement grants under Nasdaq Rule 5635(c)(4)
Alpha Cognition Inc. announced inducement grants approved by its Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 09:00 PM UTC
L
Alpha Cognition reports Q2 2026 revenue, trims opex guidance
Alpha Cognition reported about $6 million in net product revenue for Q2 2026, said it reduced full-year 2026 operating expense guidance to $50 million-$54 million, and cited 94% GAAP gross product margin.
EARNINGS | Aug 13, 2026, 09:20 PM UTC
L
Alpha Cognition (ACOG) Reports Q2 2026 Results, Operational Update
Alpha Cognition Inc. (ACOG) reports its second quarter 2026 financial results and provides an operational update, with no additional figures or details supplied in the feed.
EARNINGS | Aug 13, 2026, 08:11 PM UTC
H
ACOG Receives European Patent
ACOG gets patent for Alzheimer's treatment
EQUITY | Jul 29, 2026, 12:33 PM UTC
H
Alpha Cognition Receives European Patent
Alpha Cognition gets patent for Alzheimer's treatment
EQUITY | Jul 29, 2026, 12:31 PM UTC
L
Alpha Cognition initiated with an Outperform at Raymond James
Raymond James analyst Ryan Deschner initiated coverage of Alpha Cognition with an Outperform rating and $20 price target. Alpha Cognition markets Zunveyl, a prodrug of FDA-approved galantamine, which is indicated for the
REGULATION | Jul 10, 2026, 10:12 AM UTC